Skip to content
lifestyle.paraskevas.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oryzon Genomics, S.A.
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
July 1, 2026
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
June 11, 2026
ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
June 2, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
May 14, 2026
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
February 13, 2026
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
February 12, 2026
←
Previous Page
1
2